Bedside Monitoring of Microenvironmental Changes in Infected Pancreatic Collections
- Sponsor
- Martin Harazim
- Study ID
- NCT07131917
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Pancreatitis
- Walled Off Pancreatic Necrosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Miniaturized Intracavitary Monitoring Probe — DEVICEA sterile, miniaturized, biocompatible monitoring probe (≤1.5 mm diameter) is temporarily introduced into the cavity of an infected walled-off pancreatic necrosis (WOPN) during standard percutaneous drainage. The device is designed to measure local microenvironmental parameters in situ, such as acidity and related indicators, without interfering with fluid evacuation. Measurements are performed intermittently or continuously for up to 72 hours and are used solely for observational purposes. This intervention is distinct from standard WOPN management, as it allows real-time assessment of local physicochemical conditions, which are not accessible through systemic biomarkers or imaging alone.
Study Details
This pilot clinical study aims to assess the feasibility and clinical relevance of bedside monitoring of microenvironmental conditions within infected walled-off pancreatic necrosis (WOPN). WOPN is a serious complication of acute pancreatitis, often associated with infection, organ failure, and the need for drainage or surgical intervention. Although infection is a key factor in prognosis, little is known about the local chemical environment inside the infected collections. In this study, a sterile, miniaturized probe will be temporarily introduced into the necrotic cavity during standard percutaneous drainage. The goal is to record local microenvironmental parameters (such as acidity or related values) and monitor their changes over time. By comparing these values with clinical data (e.g., inflammatory markers, microbiology, need for surgery), the study aims to determine whether such measurements can provide additional information about infection severity and treatment response. The study does not involve any experimental treatment. All patients will receive standard medical care, including antibiotics, imaging, and drainage according to international guidelines. Participation is voluntary. Only patients who provide informed consent will be enrolled.
Key Dates
- Start date
- Nov 1, 2025
- Status verified
- Aug 2025
- Primary completion
- May 28, 2026
- Completion
- Jun 15, 2026
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: Bedside Microenvironment Monitoring ArmParticipants in this arm will undergo standard percutaneous drainage of infected walled-off pancreatic necrosis (WOPN) as per clinical indication. In addition, a sterile, biocompatible micro-monitoring probe will be temporarily introduced into the collection to measure local microenvironmental parameters. Measurements will be performed intermittently or continuously for up to 72 hours without compromising drainage function. No investigational drug or therapeutic intervention is administered.
Primary Outcome Measure
Feasibility and Safety of Intracavitary Monitoring During Percutaneous Drainage of Infected WOPN [ Time Frame: From Day 0 (drainage procedure) to Day 3 or removal of the probe, whichever occurs first ]
Central Contacts
- Martin Harazim, MD+420 532 233 052
Related Studies
- Pancreas Registry and High Risk RegistryRecruiting · Icahn School of Medicine at Mount Sinai · New York, New York
- Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational StudiesRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Study of Blood Based Biomarkers for Pancreas AdenocarcinomaRecruiting · Memorial Sloan Kettering Cancer Center · Middletown, New Jersey
- Intermittent Fasting for PancreatitisNot Yet Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida